Windtree Therapeutics, Inc. Operating CF per Share

Operating CF per Share of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating CF per Share growth rates and interactive chart. Total operating cash flow in a period divided by the weighted average number of shares outstanding. A company with $100 million in operating cash flow and 10 million weighted average shares will have operating cash flow per share of $10.


Highlights and Quick Summary

  • Operating CF per Share for the quarter ending June 29, 2020 was -0.47 (a 16.54% increase compared to previous quarter)
  • Year-over-year quarterly Operating CF per Share increased by 30.86%
  • Annual Operating CF per Share for 2019 was -2.26 (a -78.58% decrease from previous year)
  • Annual Operating CF per Share for 2018 was -10.54 (a -82.84% decrease from previous year)
  • Annual Operating CF per Share for 2017 was -61.43 (a -74.63% decrease from previous year)
  • Twelve month Operating CF per Share ending June 29, 2020 was -1.44 (a -7.47% decrease compared to previous quarter)
  • Twelve month trailing Operating CF per Share decreased by -38.96% year-over-year
Trailing Operating CF per Share for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-1.44 -1.56 -2.26 -2.37
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating CF per Share of Windtree Therapeutics, Inc.

Most recent Operating CF per Shareof WINT including historical data for past 10 years.

Interactive Chart of Operating CF per Share of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Operating CF per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -0.47 -0.4
2019 -0.5 -0.36 -0.62 -0.82 -2.26
2018 -4.13 -2.61 -3.01 -2.37 -10.54
2017 -14.03 -13.89 -32.72 -48.88 -61.43
2016 -50.07 -59.86 -66.47 -67.29 -242.17
2015 -65.86 -59.79 -94.77 -84.99 -288.58
2014 -99.53 -106.79 -98.61 -101.97 -406.41
2013 -152.49 -153.02 -174.5 -197.21 -614.8
2012 -193.24 -190.54 -163.26 -171.7 -701.15
2011 -204.59 -210.17 -212.34 -234.68 -840.67
2010 -406.23 -321.1 -576.46 -586.97 -1758.7

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.